Daniel Lynch

Daniel Lynch has an estimated net worth of $37 Million. This is based on reported shares across multiple companies, which include BIND Therapeutics, Inc, 2seventy bio, Inc., Blueprint Medicines Corp, SpringWorks Therapeutics, Inc., bluebird bio, Inc., Translate Bio, Inc., Omega Alpha SPAC, Surface Oncology, Inc., Xilio Therapeutics, Inc., Eleven Biotherapeutics, Inc., and IMCLONE SYSTEMS INC/DE.

2017 was Daniel Lynch's most active year for acquiring shares with 22 total transactions. Daniel Lynch's most active month to acquire stocks was the month of May. 2017 was Daniel Lynch's most active year for disposing of shares, totalling 49 transactions. Daniel Lynch's most active month to dispose stocks was the month of July. 2015 saw Daniel Lynch paying a total of $85,542.40 for 82,089 shares, this is the most they've acquired in one year. In 2017 Daniel Lynch cashed out on 109,000 shares for a total of $5,402,992.03, their largest year based on trade value.